Lirafugratinib EMA Filing: Superior Single-Arm Numbers, But Third-Entrant HTA Gauntlet Awaits

Elevar Submits Lirafugratinib MAA to EMA for Cholangiocarcinoma

Elevar Therapeutics has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for lirafugratinib. This submission seeks approval for lirafugratinib as a second-line treatment for patients with advanced/metastatic cholangiocarcinoma (CCA) harboring FGFR2 fusions or rearrangements. The application is supported by data from the Phase 1/2 ReFocus study, which demonstrated an objective response rate (ORR) of 46.5% by independent review committee. Key secondary endpoints included a median duration of response of 11.8 months, median progression-free survival of 11.3 months, and median overall survival of 22.8 months. This follows a prior New Drug Application to the U.S. FDA in January 2026, which received Priority Review with a PDUFA target action date of September 25, 2026.

• Regulatory Milestones in EU and US: Elevar Therapeutics has advanced lirafugratinib's regulatory pathway by submitting a Marketing Authorization Application to the European Medicines Agency. This follows a New Drug Application to the U.S. FDA in January 2026, which was granted Priority Review and has a PDUFA target action date of September 25, 2026. Lirafugratinib previously received Orphan Drug Designation in 2022 and Breakthrough Therapy Designation in 2023 from the FDA, underscoring its potential to address an unmet medical need.
• Compelling Clinical Efficacy in CCA: The MAA is based on robust data from the Phase 1/2 ReFocus study, which evaluated lirafugratinib in advanced/metastatic FGFR2 fusion+ CCA patients who had received prior systemic therapy. The study achieved a significant objective response rate (ORR) of 46.5% as assessed by an independent review committee. Furthermore, the drug demonstrated durable responses with a median duration of response of 11.8 months, a median progression-free survival of 11.3 months, and a median overall survival of 22.8 months, highlighting its meaningful clinical activity.
• Differentiated Mechanism and Safety Profile: Lirafugratinib is characterized as a highly selective, irreversible FGFR2 inhibitor, distinguishing it from existing pan-FGFR therapies that broadly inhibit multiple FGFRs. This selectivity contributes to a differentiated safety profile, with lower rates of common adverse events associated with non-selective FGFR inhibitors. Specifically, rates of hyperphosphatemia and diarrhea were 20.7% and 21.6%, respectively, suggesting improved tolerability for patients.

Addressing Unmet Needs in FGFR2+ CCA with Lirafugratinib

Despite meaningful progress with first- and second-line FGFR-targeted therapies, advanced FGFR2-rearranged cholangiocarcinoma continues to present critical unmet needs driven by the near-universal emergence of acquired resistance and the molecular heterogeneity of resistant disease. The following areas represent the key gaps and populations under active investigation.

• Patients progressing on first-generation FGFR inhibitors (acquired resistance population): Acquired resistance to both reversible inhibitors (pemigatinib, infigratinib, erdafitinib) and the irreversible inhibitor futibatinib is predominantly driven by polyclonal secondary FGFR2 kinase domain mutations, detected in 60% of patients across published reports. N550 molecular brake and V565 gatekeeper mutations account for 63% and 47% of all FGFR2 kinase domain mutations at resistance, respectively. This population lacks a well-established standard of care after FGFR inhibitor failure, representing a primary target for next-generation agents such as lirafugratinib.

• Patients with bypass signaling–mediated resistance: Off-target alterations in the PI3K/mTOR and MAPK pathways are detected in a substantial proportion of patients at progression, often co-occurring with on-target FGFR2 mutations. In the lirafugratinib-naïve context specifically, RTK-MAPK bypass alterations emerged in 9 of 16 patients at resistance. This population is being targeted through rational combination strategies, including EGFR/ERBB blockade, and molecularly oriented approaches such as everolimus in patients with TSC1 or PIK3CA mutations.

• First-line FGFR2-rearranged advanced CCA: Although gemcitabine plus cisplatin (with or without durvalumab) remains standard first-line therapy, the FIGHT-302 phase 3 trial demonstrated that first-line pemigatinib produced a median PFS of 8.3 months versus 6.8 months for chemotherapy (hazard ratio 0.58 [95% CI, 0.39–0.87]; nominal P=0.0078) and an objective response rate of 47% versus 15%, with a median duration of response of 14.2 versus 6.3 months. Despite these results, median OS was similar (24.4 versus 25.0 months), underscoring that moving targeted therapy earlier has not yet translated into a survival benefit and that the optimal first-line strategy for this molecularly defined population remains an open question.

• Rare and pediatric FGFR2-fusion–positive populations: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) with FGFR2 fusions represents an extremely rare and underinvestigated subtype, particularly in children, for whom no standard systemic treatment has been established. A reported case of a 14-year-old with an FGFR2-PRDM16 fusion—not previously described as a common FGFR2 fusion—treated with pemigatinib plus gemcitabine and cisplatin achieved a partial response and survived 26 months, highlighting both the potential of FGFR-directed therapy and the absence of evidence-based guidance in this population.

• Longitudinal molecular monitoring and treatment sequencing: The growing use of circulating tumor DNA (ctDNA) as a noninvasive tool for detecting resistance mutations and guiding sequential therapy is an active area of development. Resistance profiles differ markedly between pan-FGFR and selective FGFR2 inhibitors—lirafugratinib resistance is characterized by increased M538I and L618F mutations and more frequent RTK-MAPK bypass alterations relative to pan-FGFR inhibitor resistance—underscoring the need for prospective ctDNA-guided sequencing strategies to optimize treatment across lines.

Lirafugratinib's Clinical Profile from the Pivotal ReFocus Study

Several targeted therapies have demonstrated meaningful clinical activity in advanced/metastatic cholangiocarcinoma (CCA) harboring FGFR2 fusions or rearrangements, spanning both second-line and first-line settings. The studies below capture key efficacy and safety findings across pivotal and real-world investigations.

Lirafugratinib's Differentiated MoA in FGFR2+ CCA Landscape

The knowledge base does not have sufficient information to answer this question.

Selective FGFR2 Inhibition: A New Frontier in CCA

The recent submission of a Marketing Authorization Application for lirafugratinib to the European Medicines Agency, following a Priority Review designation from the U.S. FDA, signals a significant potential shift in the treatment landscape for advanced/metastatic cholangiocarcinoma (CCA) with FGFR2 fusions or rearrangements. This move by Elevar Therapeutics introduces a novel, first-in-class FGFR2-selective inhibitor into a therapeutic area where existing options, while effective, face challenges.

Current FGFR inhibitors, such as pemigatinib, infigratinib, and futibatinib, have demonstrated clinical benefit in FGFR2-altered CCA. However, their efficacy is often curtailed by the inevitable development of acquired resistance, frequently driven by secondary FGFR2 kinase domain mutations like N550 and V565 variants. Furthermore, pan-FGFR inhibition can lead to off-target toxicities, notably hyperphosphatemia, which can impact patient quality of life.

Lirafugratinib's selectivity for FGFR2 is designed to address these limitations. Clinical data from the ReFocus study, supporting the MAA, reported an objective response rate of 46.5%, a median duration of response of 11.8 months, and a median overall survival of 22.8 months. These outcomes are highly encouraging for a second-line setting in a disease known for its aggressive nature and poor prognosis. The drug's ability to retain activity against some of the mutations that confer resistance to pan-FGFR inhibitors represents a crucial advantage.

However, the emergence of resistance remains a persistent challenge. Research indicates that while lirafugratinib may circumvent some common pan-FGFR resistance mutations, it can lead to the development of distinct FGFR2 kinase domain mutations (e.g., M538I, L618F) and a higher frequency of RTK-MAPK bypass alterations. This highlights the ongoing need for:

• Continuous genomic monitoring: Utilizing tools like circulating tumor DNA analysis to detect evolving resistance mechanisms.

• Development of combination strategies: Exploring therapies that can target these bypass pathways, potentially extending the duration of response.

The anticipated approval of lirafugratinib would not only provide a new, potentially more durable and better-tolerated option for patients but also intensify the competitive environment for targeted CCA therapies. Pharma teams will need to consider how this selective approach impacts treatment sequencing and the potential for combination regimens to overcome the complex landscape of acquired resistance.